Baenke F, Chaneton B, Smith M, Van Den Broek N, Hogan K, Tang H, et al
As with nearly any emerging field of study, there are methodological inconsistencies which can significantly impact measures of analyte(s)
Immediately after a Rhinoplasty This patient is shown immediately after a Rhinoplasty to reduce her dorsal hump, refine asymmetries, and improve projection issues in her tip
Retatrutide Clinical Research Findings The clinical development program for retatrutide has produced compelling data across multiple research endpoints: Weight Loss Efficacy: Phase 2 trials showed dose-dependent weight reduction ranging from 8.7% at the lowest dose to 24.2% at the highest dose over 48 weeks Metabolic Improvements: Participants demonstrated improvements in glycemic control, lipid profiles, and blood pressure measurements Safety Profile: Gastrointestinal effects (nausea, vomiting, diarrhea) were the most common adverse events, occurring in 60-80% of participants but generally rated as mild to moderate in severity Sustained Effects: Weight loss continued throughout the trial period without evidence of plateau, suggesting ongoing metabolic benefits These findings have positioned retatrutide as a leading candidate for advanced metabolic research
